

Fertilizers: CY25e Preview – Payout up, profit rise by 15% YoY

Tuesday, January 27, 2026



EUROMONEY

Euromoney Market Leaders
Investment Banking (Notable) -
2022

A PAC
Insider

Best Equity Market Consultants
Pakistan 2022



**Global
Business
Outlook**

Most Innovative Corporate Finance
Advisory Firm - Pakistan 2022
Fastest Growing Asset Manager -
Pakistan 2022



**CFA Society
Pakistan**

Best Brokerage House 2017
Best Brokerage House 2016 (Runner-up)
Best Analyst & Trader 2013 (Runner-up)

ASIAMONEY

Sector Coverage of Bank,
Insurance, Power, Macroeconomics,
Small Caps, Materials
Runner Up

CY25e earnings expected to surge by 15% YoY

Fertilizer earnings to increase by 15% YoY

We project that earnings across the BMA Fertilizer universe will rise by 15% YoY to PKR 149bn in CY25. The growth is expected to be supported by an 18% YoY increase in other income, a 2.3% YoY expansion in urea offtake, and a sharp 41% YoY surge in CAN volumes. On a QoQ basis, earnings are forecast to climb by 30%, largely driven by stronger urea offtake.

Better Urea offtake

Urea sales rose sharply by 26% YoY and 36% QoQ to 2.5mn tons in 4QCY25. In contrast, DAP offtake is projected to decline by 22% YoY, though it is expected to rebound by 60% QoQ to 543k tons during the same period. The increase in urea sales was largely driven by aggressive discounting by manufacturers, particularly EFERT, according to our channel checks.

Fauji Fertilizer Company (FFC)

We expect FFC to post an unconsolidated EPS of PKR 16.1 in 4QCY25e, up 32% YoY and 19% QoQ. The earnings growth is primarily driven by higher urea offtake and improved gross margins amid lower DAP sales. We also anticipate a cash dividend of PKR 11 per share to be announced with the results.

Engro Fertilizers (EFERT)

We estimate EFERT's consolidated EPS at PKR 7.75 in 4QCY25e, up 1% YoY. The YoY growth is driven by substantially higher urea sales, although aggressive discounting weighed on gross margins. On a QoQ basis, earnings are projected to surge by 78%, supported by a 76% increase in urea offtake. We also expect the company to declare a cash dividend of PKR 8.0 per share with the results.

Fatima Fertilizer Company Limited (FATIMA)

We estimate FATIMA's consolidated EPS at PKR 7.2 in 4QCY25e, marking a 10% YoY and 25% QoQ increase. The strong earnings performance is driven by a 30% YoY rise in urea offtake and an 86% surge in CAN volumes. Additionally, other income for CY25e is expected to grow by 33% YoY, supporting full-year EPS of PKR 20.92. We also anticipate a cash dividend of PKR 4.50 per share to be announced with the results.

Pakistan Fertilizer Earnings Estimates					
PkR	CY25E	CY24A	YoY	4QCY25E	QoQ
FFC	56.6	49.5	24%	16.1	19%
EFERT*	18.4	21.2	-13%	7.7	78%
FATIMA*	20.9	17.3	21%	7.2	25%

Source: Company Accounts, BMA Research, *Consolidated

Pakistan Urea Off-take in CY25					
K Tons	CY25A	CY24A	YoY	4QCY25A	QoQ
FFC	2,889	3,063	-6%	934	12%
EFERT	2,314	2,027	14%	1,034	76%
FATIMA	1,163	950	22%	427	33%
Total	6,730	6,577	2%	2,526	36%

Source: NDFC, BMA Research

Pakistan DAP Off-take in CY25					
K Tons	CY25A	CY24A	YoY	4QCY25A	QoQ
FFC	834	995	-16%	293	16%
EFERT	166	306	-46%	71	4.1x
FATIMA	34	51	-33%	6.7	12%
Total	1,339	1,637	-18%	543	60%

Source: NDFC, BMA Research

Urea & DAP Prices in 4QCY25					
PkR/Bag	4QCY25A	4QCY24A	YoY	3QCY25A	QoQ
Urea	4,293	4,500	-5%	4,335	-1%
DAP	14,540	11,970	21%	13,449	8%

Source: NDFC, BMA Research

Ajeet Kumar

Research Analyst

BMA Capital Management Ltd.

E-mail: ajeet.kumar@bmacapital.com

This research report is for information purposes only and does not constitute nor is it intended as an offer or solicitation for the purchase or sale of securities or other financial instruments. Neither the information contained in this research report, nor any future information made available with the subject matter contained herein will form the basis of any contract. Information and opinions contained herein have been compiled or arrived at by BMA Capital Management Limited from publicly available information and sources that BMA Capital Management Limited believed to be reliable. Whilst every care has been taken in preparing this research report, no research analyst, director, officer, employee, agent or adviser of any member of BMA Capital Management Limited gives or makes any representation, warranty or undertaking, whether express or implied, and accepts no responsibility or liability as to the reliability, accuracy or completeness of the information set out in this research report. Any responsibility or liability for any information contained herein is expressly disclaimed. All information contained herein is subject to change at any time without notice. No member of BMA Capital Management Limited has an obligation to update, modify or amend this research report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, projection, forecast or estimate set forth herein, changes or subsequently becomes inaccurate, or if research on the subject company is withdrawn. Furthermore, past performance is not indicative of future results.

The investments and strategies discussed herein may not be suitable for all investors or any particular class of investor. Investors should make their own investment decisions using their own independent advisors as they believe necessary and based upon their specific financial situations and investment objectives when investing. Investors should consult their independent advisors if they have any doubts as to the applicability to their business or investment objectives of the information and the strategies discussed herein. This research report is being furnished to certain persons as permitted by applicable law, and accordingly may not be reproduced or circulated to any other person without the prior written consent of a member of BMA Capital Management Limited. This research report may not be relied upon by any retail customers or person to whom this research report may not be provided by law. Unauthorized use or disclosure of this research report is strictly prohibited. Members of BMA Capital Management and/or their respective principals, directors, officers and employees may own, have positions or effect transactions in the securities or financial instruments referred herein or in the investments of any issuers discussed herein, may engage in securities transactions in a manner inconsistent with the research contained in this research report and with respect to securities or financial instruments covered by this research report, may sell to or buy from customers on a principal basis and may serve or act as director, placement agent, advisor or lender, or make a market in, or may have been a manager or a co-manager of the most recent public offering in respect of any investments or issuers of such securities or financial instruments referenced in this research report or may perform any other investment banking or other services for, or solicit investment banking or other business from any company mentioned in this research report. Investing in Pakistan involves a high degree of risk and many persons, physical and legal, may be restricted from dealing in the securities market of Pakistan. Investors should perform their own due diligence before investing. No part of the compensation of the authors of this research report was, is or will be directly or indirectly related to the specific recommendations or views contained in the research report. By accepting this research report, you agree to be bound by the foregoing limitations.

BMA Capital Management Limited and / or any of its affiliates, which operate outside Pakistan, do and seek to do business with the company(s) covered in this research document. Investors should consider this research report as only a single factor in making their investment decision. BMA Research Policy prohibits research personnel from disclosing a recommendation, investment rating, or investment thesis for review by an issuer/company prior to the publication of a research report containing such rating, recommendation or investment thesis.

Stock Rating

Investors should carefully read the definitions of all rating used within every research reports. In addition, research reports carry an analyst's independent view and investors should ensure careful reading of the entire research reports and not infer its contents from the rating ascribed by the analyst. Ratings should not be used or relied upon as investment advice. An investor's decision to buy, hold or sell a stock should depend on said individual's circumstances and other considerations. BMA Capital Limited uses a three-tier rating system: i) Buy, ii) Neutral and iii) Underperform (new rating system effective Jan 1'18) with our rating being based on total stock returns versus BMA's index target return for the year. A table presenting BMA's rating definitions is given below:

Old rating system

Valuation Methodology

To arrive at our period end target prices, BMA Capital uses different valuation methodologies including

- Discounted cash flow (DCF, DDM)
- Relative Valuation (P/E, P/B, P/S etc.)
- Equity & Asset return based methodologies (EVA, Residual Income etc.)

BMA CAPITAL MANAGEMENT LIMITED TREC HOLDER AT PAKISTAN STOCK EXCHANGE LIMITED

HEAD OFFICE:

Level 8, Unitower, I.I. Chundrigar Road, Karachi - 74000, Pakistan
Tel: +92 21 111 262 111 | Fax: +92 21 3243 0748 | www.bmacapital.com | info@bmacapital.com

Stock Exchange Branch:

Room 141, Pakistan Stock Exchange,
Stock Exchange Road, Karachi.
Tel: (021) 32410617

Awami Markaz Branch:

G13, Ground floor, Awami Markaz,
Shahrah-e-Faisal Karachi.
Tel: (021) 34300578

Islamabad Branch:

104, 1st Floor, 82-East,
Muhammad Gulistan Khan House,
Fazel e Haq, Blue Area, Islamabad
Pakistan
Tel: (051) 280 2354-5
Fax: (051) 280 2356

Faisalabad Branch:

Mezzanine Floor, State Life Building #2,
Plot No. 833 Liaquat Road, Faisalabad.
Tel: (041) 2612261-5.

Peshawar Branch:

Shop No.F1 & F2, 1st Floor Mall Tower
35,
The Mall Peshawar Cantt.
Tel: (091) 5274770-72

Bahadurabad Branch:

Office # 3, Mezzanine Floor,
Akber Manzil, Main Bahadurabad
Roundabout, Karachi
Tel: (021) 3486 0393-98
Fax: (021) 3493 1396

Lahore Cavalry Branch:

Office No. 74, 2nd Floor, Commercial
Area, Main Cavalry Ground, Lahore Cantt,
Lahore.
Tel: (042) 3667 6614-20
Fax: (042) 3661 9912

Sialkot Branch:

2nd Floor, Sialkot Business & Commerce
Centre, Paris Road, Sialkot, Adjacent to
Sialkot Chamber of Commerce.
Tel: (052) 4260091-94

Gujranwala Branch:

51-H block Near Standard Chartered
Bank
Trust Plaza GT road Gujranwala.
Tel: (055) 3848501-05

Abbottabad Branch:

Gohar Son's Arcade 1st Floor Office# 4,
Supply Bazar Sikandarabad Abbottabad,
PK. Tel: (0992) 400346-47

Gulshan-e-Iqbal Branch:

Commercial Office premises bearing,
B-29 Mezzanine Floor 13/A, Main
University Road, Gulshan-e-Iqbal
Karachi.
Tel: (021) 34825023

Lahore Gulberg Branch:

Commercial Office No. 402, 7th Floor,
Mega Tower 63-B, Main Boulevard,
Gulberg II, Lahore.
Tel: (042) 35762953-57

Multan Branch:

Office No. 607/A, 6th Floor,
The United Mall, Plot No. 74
Abdali Road, Multan
Tel: (061) 457 6611-15
Fax: (061) 457 6615

Chakwal Branch:

Office No. 12, 1st Floor, Ejaz Plaza,
Talagang Road Chakwal.
Tel: (0543) 553850, 0543-
543720,0543-543721.

Gujar Khan Branch:

1st Floor, Office# 101 & 102, Akbar
Kayani Plaza, GT Road,GujarKhan.
Tel: (051) 3762083

North Nazimabad Branch:

D-14 Office No 02, 2nd Floor Block H,
MCB Building, Near 5 Star Round About,
North Nazimabad Karachi.
Tel: (021) 36672301-00.

Lahore LSE Branch:

1st Floor Room# 110-111, LSE Building,
19- Khayaban-e-Aiwan-e-Iqbal, Lahore.
Tel: (042) 36280931-34

Sargodha Branch:

Ground floor, Shan Plaza, Block No 16,
Main Khushab Road, Near Allied Bank
Limited, Sargodha.
Tel: (048) 3767 817-18

Jhelum:

2nd Floor, Khalid Plaza, Plot#7/89,
Kazim Kamal Road, Jhelum, Punjab.
Tel: (054) 4620594-97

Bahawalpur Branch:

Plot # 13-A, 1st Floor, Office # 2,
Model Town B, Bahawalpur
Tel: (062) 2883158, 2884158